These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 23295056

  • 1. Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial.
    Yim HJ, Seo YS, Yoon EL, Kim CW, Lee CD, Park SH, Lee MS, Park CK, Chae HB, Kim MY, Baik SK, Kim YS, Kim JH, Lee JI, Lee JW, Hong SP, Um SH.
    Liver Int; 2013 Feb; 33(2):244-54. PubMed ID: 23295056
    [Abstract] [Full Text] [Related]

  • 2. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir.
    Ong A, Wong VW, Wong GL, Chan HY, Tse CH, Chan HL.
    Aliment Pharmacol Ther; 2011 Oct; 34(8):972-81. PubMed ID: 21883327
    [Abstract] [Full Text] [Related]

  • 3. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
    Vassiliadis TG, Giouleme O, Koumerkeridis G, Koumaras H, Tziomalos K, Patsiaoura K, Grammatikos N, Mpoumponaris A, Gkisakis D, Theodoropoulos K, Panderi A, Katsinelos P, Eugenidis N.
    J Gastroenterol Hepatol; 2010 Jan; 25(1):54-60. PubMed ID: 19780875
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine.
    Manolakopoulos S, Bethanis S, Koutsounas S, Goulis J, Vlachogiannakos J, Christias E, Saveriadis A, Pavlidis C, Triantos C, Christidou A, Papatheodoridis G, Karamanolis D, Tzourmakliotis D.
    Aliment Pharmacol Ther; 2008 Feb 01; 27(3):266-73. PubMed ID: 17988233
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.
    Lee JM, Park JY, Kim DY, Nguyen T, Hong SP, Kim SO, Chon CY, Han KH, Ahn SH.
    Antivir Ther; 2010 Feb 01; 15(2):235-41. PubMed ID: 20386079
    [Abstract] [Full Text] [Related]

  • 11. Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues.
    Lim YS, Lee TH, Heo NY, Shim JH, Lee HC, Suh DJ.
    Antivir Ther; 2012 Feb 01; 17(1):53-60. PubMed ID: 22267469
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir.
    Kwak MS, Choi JW, Lee JS, Kim KA, Suh JH, Cho YS, Won SY, Park BK, Lee CK.
    J Viral Hepat; 2011 Oct 01; 18(10):e432-8. PubMed ID: 21914060
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
    Zhou HJ, Li SG, Wen FY, Yang XY, Wu JL, Tan B, Fu J.
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug 01; 17(8):564-8. PubMed ID: 19719911
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.
    Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, Peng CY, Myers RP, Brown RS, Jeffers L, Tsai N, Bialkowska J, Tang S, Beebe S, Cooney E.
    Hepatology; 2011 Jul 01; 54(1):91-100. PubMed ID: 21503940
    [Abstract] [Full Text] [Related]

  • 18. Treatment of lamivudine-resistant chronic hepatitis B infection: a multicenter retrospective study.
    Lee SJ, Yim HJ, Hwang SG, Seo YS, Kim JH, Yoon EL, Lee JM, Kim BH, Park SJ, Park YM, Kim HS, Lee SH, Ahn SH, Lee JI, Lee JW, Kim IH, Kim HS, Hong SP.
    Scand J Gastroenterol; 2013 Feb 01; 48(2):196-204. PubMed ID: 23194375
    [Abstract] [Full Text] [Related]

  • 19. Long-term efficacy of entecavir plus adefovir combination therapy versus entecavir monotherapy in adefovir refractory chronic hepatitis B patients with prior lamivudine resistance.
    Seo SY, Kim IH, Sohn JY, Lee S, Kim SH, Kim SW, Lee SO, Lee ST, Kim DG.
    Intervirology; 2014 Feb 01; 57(1):8-16. PubMed ID: 23988634
    [Abstract] [Full Text] [Related]

  • 20. Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir.
    Seto WK, Liu K, Fung J, Wong DK, Yuen JC, Hung IF, Lai CL, Yuen MF.
    Antivir Ther; 2012 Feb 01; 17(7):1255-62. PubMed ID: 22951420
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.